Recombinant Human HLA-B*27:05&B2M Monomer Protein (HEK293)，Avi & His

The research into the recombinant protein HLA-B*27:05 and beta-2-microglobulin (B2M) monomer primarily stems from its critical role in understanding autoimmune diseases, particularly ankylosing spondylitis (AS). HLA-B27 is a major histocompatibility complex (MHC) class I molecule that is strongly associated with AS, a chronic inflammatory condition that primarily affects the spine and sacroiliac joints. The structure and function of HLA-B*27:05, in conjunction with B2M, are essential for presenting antigens to T cells, thus triggering immune response. However, the presence of the HLA-B27 allele is not solely responsible for AS; it is believed that certain conformational and molecular characteristics of the HLA-B27 molecule may predispose individuals to autoimmune pathology. The creation of HLA-B*27:05 and B2M monomer as a recombinant protein allows for detailed structural and functional studies, facilitating the exploration of its epitopes and interaction with T cell receptors. Furthermore, understanding the molecular basis of how HLA-B*27:05 contributes to disease mechanisms may uncover new therapeutic targets and diagnostics for AS and related conditions, making this research pivotal for advancing both basic immunology and clinical outcomes in patients with HLA-B27-related disorders.